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Oxidative stressPiracetam is a prototype of nootropic drugs used to improve cognitive impairment. However, recent studies sug-
gest that piracetam can have analgesic and anti-inﬂammatory effects. Inﬂammatory pain is the result of a process
that depends onneutrophilmigration, cytokines andprostanoids release and oxidative stress.We analyzewhether
piracetam has anti-nociceptive effects and its mechanisms. Per oral pretreatment with piracetam reduced in a
dose-dependent manner the overt pain-like behavior induced by acetic acid, phenyl-p-benzoquinone, formalin
and complete Freund's adjuvant. Piracetam also diminished carrageenin-induced mechanical and thermal
hyperalgesia, myeloperoxidase activity, and TNF-α-induced mechanical hyperalgesia. Piracetam presented anal-
gesic effects as post-treatment and local paw treatment. The analgesic mechanisms of piracetam were related to
inhibition of carrageenin- and TNF-α-induced production of IL-1β as well as prevention of carrageenin-induced
decrease of reduced glutathione, ferric reducing ability and free radical scavenging ability in the paw. These results
demonstrate that piracetampresents analgesic activity upon a variety of inﬂammatory stimuli by amechanismde-
pendent on inhibition of cytokine production and oxidative stress. Considering its safety and clinical use for cogni-
tive function, it is possible that piracetam represents a novel perspective of analgesic.
© 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Acute inﬂammatory pain is characterized by sensitization of
nociceptors resulting in hyperalgesia and allodynia, which is exacerbat-
ed pain intensity in response to painful stimuli, and pain to stimuli that
is not normally painful, respectively (Millan, 1999). Inﬂammatory stim-
uli such as carrageenin induce a cascade of inﬂammatory cytokines
resulting in inﬂammatory hyperalgesia. For instance, carrageenin in-
duces the production of TNF-α, which triggers IL-1β production,
which in turn, activates the synthesis of PGE2 (Cunha et al., 2005).
These inﬂammatory mediators are responsible for sensitization of
nociceptors and activation of second messenger pathway (cAMP, PKA,
and PKC) which reduce the nociceptor threshold and increase neuronal
membrane excitability, facilitating the primary nociceptor activationhiazoline 6-sulfonate); AMPA,
; cAMP, cyclic adenosine
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vier OA license.and impulse transmission, resulting in hyperalgesia (Cury et al., 2011;
Verri et al., 2006a; Villarreal et al., 2009).
Neutrophils are great contributors to acute inﬂammatory
hyperalgesia. There is evidence that neutrophils recruited by cytokines,
endothelin-1, complement component C5a and leukotriene B4 contribute
to hyperalgesia by further producing nociceptive mediators such as PGE2
(Cunha et al., 2008; Guerrero et al., 2008; Ting et al., 2008; Verri et al.,
2009). Therefore, blockade of neutrophil recruitment reduces inﬂamma-
tory hyperalgesia (Cunha et al., 2008). Another important component of
inﬂammatory pain is the oxidative stress with the generation of mole-
cules such as hydrogen peroxide, superoxide anion, and peroxinitrite,
which are produced in response to stimuli and can promote hyperalgesia
(Keeble et al., 2009; Ndengele et al., 2008;Wang et al., 2004). Under nor-
mal conditions, oxidative stress products are counteracted by endoge-
nous antioxidant systems, which include enzymes (superoxide
dismutase, glutathione reductase, and catalase) and other molecules
(GSH, bilirubin, and uric acid) (Limón-Pacheco and Gonsebatt, 2009).
During inﬂammatory processes, the levels of oxidative stress products ex-
ceed endogenous antioxidant system overwhelming their capacity and
producing an imbalance that mediates tissue injury and inﬂammatory
pain (Keeble et al., 2009; Ndengele et al., 2008; Wang et al., 2004).
Nootropic drugs improve cognitive functions such as learning and
memory (Genkova-Papazova and Lazarova-Bakarova, 1996; Winblad,
2005). Piracetam, 2-oxo-1-pyrrolidine acetamide, is the prototype of
nootropic drug derived from GABA, however its mechanism of action
does not seem to be related to GABA and the precise mechanism of
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piracetam acts by restoring the membrane ﬂuidity and by promoting
AMPA receptor allosteric modulation (Winblad, 2005).
To our knowledge, the only evidence that piracetam inhibits noci-
ceptive behavior demonstrated that it reduces acetic acid-induced
writhing response by mechanisms involving adenosine receptors, and
that blockade of muscarinic, adrenergic and opioid receptors potenti-
ates the antinociceptive effect of piracetam (Abdel-Salam, 2006). In
contrast, levetiracetam, an antiepileptic drug α-etil analogue of pirace-
tam, did not affect formalin-induced nociceptive response (Munro et al.,
2007) while it reduced carrageenin-induced hyperalgesia by mecha-
nisms mediated at least in part by direct/indirect activation of GABAA,
opioid, serotoninergic and adrenergic receptors (Micov et al., 2010). It
is noteworthy to mention that these studies applied models of inﬂam-
matory pain with differences in the nociceptive endpoint and nocicep-
tive mechanisms, which explain why the antinociceptive spinal/
central mechanisms of piracetam (Abdel-Salam, 2006) contrast with
the results demonstrated for levetiracetam (Micov et al., 2010). It is
also important tomention that levetiracetam reduces the IL-1β produc-
tion in astrocytes culture (Haghikia et al., 2008) and decreases oxidative
stress in hippocampus (Oliveira et al., 2007). These results suggest that
levetiracetam and possibly piracetam can modulate additional mecha-
nisms such as the production of inﬂammatory/nociceptive molecules
that eventually would contribute to their analgesic mechanism. Fur-
thermore, piracetam inhibits the exudation induced by formalin injec-
tion in the peritoneal cavity and cell proliferation induced by cotton
pellet (Nikolova et al., 1984), indicating that it reduces peripheral in-
ﬂammation. Thus, the effect of piracetam seems not restricted to the
central nervous system.
Therefore, considering that the spinal/central antinociceptive effect
of piracetam was demonstrated in only one study (Abdel-Salam,
2006) and that it can also reduce peripheral inﬂammation (Nikolova
et al., 1984) as presented above, we propose to investigate whether pir-
acetam has antinociceptive effects in models of inﬂammatory pain and
address its peripheral antinociceptivemechanisms of action focusing on
cytokines and oxidative stress.
2. Materials and methods
2.1. Animals
Male Swiss mice, from Universidade Estadual de Londrina, Londrina,
Paraná, Brazil, weighing approximately 25 ± 5 g served as experimental
animals.Micewerehoused in standard clear plastic cageswith free access
to food (Nuvilab® from Nuvital Nutrientes, Colombo, PR, Brazil) and
water, with a light/dark cycle of 12:12 h, at 21 °C. All behavioral testing
was performed between 9 a.m. and 5 p.m. in a temperature-controlled
room. Mice were placed in a quiet room 15–30 min before the start of
testing. Themicewere used only once. Animals' care and handling proce-
dures were in accordance with the International Association for Study of
Pain (IASP) guidelines and with the approval of the Ethics Committee of
theUniversidade Estadual de Londrina. All effortsweremade tominimize
the number of animals used and their suffering. It is noteworthy that dif-
ferent experimenters prepared the solutions, made the administrations
and performed the evaluation of pain-like behavior.
2.2. Drug and reagents
The following materials were obtained from the sources indicated:
piracetam (Nootropil®) from Sanoﬁ-Aventis (Suzano, SP, Brazil); acetic
acid from Mallinckrodt Baker S.A (Mexico City, Mexico); Trolox®
(6-hydroxy-2,5,7,8-tetramethychroman-2-carboxylic acid), PBQ and
CFA from Sigma Aldrich Co. (St. Louis, MO, USA); carrageenin from FMC
Corp (Philadelphia, PA, USA); TNF-α and ELISA kits from e-Bioscience
Inc (San Diego, CA, USA); and formaldehyde fromMerck (Rio de Janeiro,
RJ, Brazil).2.3. Writhing response tests
PBQand acetic acid-inducedwrithingmodelswere performed as pre-
viously described (Collier et al., 1968; Valério et al., 2007; Verri et al.,
2008). In brief, PBQ (diluted in DMSO 2%/saline, 1890 μg/kg), acetic
acid (0.6% v/v, diluted in saline, 10 mL/kg), or vehicle was injected into
the peritoneal cavities of mice. Each mouse was placed in a large glass
cylinder and the intensity of nociceptive behavior was quantiﬁed by
counting the total number of writhings (contractions of abdominal mus-
cles accompanied by an elongation of the body and extension of the hind
limbs) occurring between 0 and 20 min after stimulus injection.
2.4. The formalin and CFA tests
The time spent licking the paw was determined between 0 and
30 min after intraplantar (i.pl.) injection of 2.5% formalin diluted in
saline 0,9% (25 μL/paw) or CFA (10 μL/paw), in similar ways and as
previously described (Dubuisson and Dennis, 1977; Mizokami et al.,
2012; Valério et al., 2009). Results were presented at 5 min interval
up to 30 min for formalin test and total time spent licking the paw be-
tween 0 and 30 min in CFA test. CFA (10 μL/paw) was also used as
stimulus to induce mechanical and thermal hyperalgesia (Mizokami
et al., 2012; Valério et al., 2009).
2.5. Electronic pressure-meter test
Mechanical hyperalgesia was tested in mice, as previously reported
(Cunha et al., 2004). Brieﬂy, mice were placed in acrylic cages
(12 × 10 × 17 cm) in a quiet room 15–30 min before the start of test-
ing. The test consisted of evoking a hindpaw ﬂexion reﬂex with a
hand-held force transducer (electronic anesthesiometer, Insight
Equipamentos, Ribeirao Preto, SP, Brazil) adapted with a 0.5 mm2 poly-
propylene tip. The investigator was trained to apply the tip perpendic-
ularly to the central area of the hindpaw with a gradual increase in
pressure. The end point was characterized by the removal of the paw
and ﬂinching movements. The stimulation of the paw was repeated
until the animal presented two similar measurements. The results are
expressed by delta (Δ) withdrawal threshold (in g) calculated by
subtracting the zero-time mean measurements from the mean mea-
surements of 1, 3, or 5 h after stimulus. Withdrawal threshold was
9.4 ± 0.2 g (mean ± SEM; n = 6) before injection of the hyperalgesic
agents (e.g. carrageenin, TNF-α or CFA).
2.6. Hot plate test
Thermal hyperalgesia was evaluated before and after stimulus.
The test was performed as previously reported (Verri et al., 2005).
In brief, mice were placed in a 10 cm wide glass cylinder on a hot
plate (Hot Plate HP-2002, Insight Equipamentos, Ribeirao Preto, SP,
Brazil) maintained at 55 °C. The reaction time was scored when the
animal jumped, ﬂinched or licked its paws. The normal latency (reac-
tion time) was 12 ± 0.7 s (mean ± SEM; n = 6). A maximum laten-
cy (cutoff) was set at 30 s to avoid tissue damage.
2.7. Neutrophil migration to the paw skin tissue (myeloperoxidase activity)
Theneutrophilmigration to pawwas indirectly evaluated by theMPO
activity kinetic-colorimetric assay (Bradley et al., 1982; Casagrande et al.,
2006). Brieﬂy, paw skin sample was collected in 50 mM K2PO4 buffer
(pH 6.0) containing 0.5% HTAB and were homogenized using
Ultra-Turrax® (IKA T10 Basic, CQA Química, Paulínea, SP). Then the ho-
mogenates were centrifuged at 16100 g for 2 min at 4 °C. 15 μL of
resulting supernatant was mixed with 200 μL of 50 mMphosphate buff-
er, pH 6.0, containing 0.167 mg/mL o-dianisidine dihydrochloride and
0.05% hydrogen peroxide and was assayed spectrophotometrically for
MPO activity determination at 450 nm (BEL SP2000UV, Photonics, São
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curve of neutrophils and presented as MPO activity (number of neutro-
phils × 104/mg of tissue).
2.8. Cytokine measurement
For cytokine measurement in paw skin, mice were terminally anes-
thetized and the skin tissueswere removed and homogenized in 500 μL
of buffer containing protease inhibitors (Verri et al., 2006b). The sam-
ples were centrifuged and IL-1β and TNF-α levels were determined in
the supernatants by enzyme-linked immunosorbent assay (ELISA)
using eBioscience kit according to the manufacturer's instructions. The
results are expressed as pg of cytokine/100 mg of paw skin.
2.9. GSH measurement
Paw skin sample was collected and maintained at −80 °C for at
least 48 h. The sample was homogenized with 200 μL of 0.02 M
EDTA. The homogenate was mixed with 25 μL of 50% trichloroacetic
acid and was homogenized three times during 15 min. The mixture
was centrifuged (15 min × 1500 g × 4 °C). The supernatant was
added to 200 μL of 0.2 M TRIS buffer, pH 8.2, and 10 μL of 0.01 M
DTNB. After 5 min, the absorbance was measured at 412 nm against
a reagent blank with no supernatant. A standard curve was
performed with standard GSH. The results are expressed as GSH per
mg of protein (Sedlak and Lindsay, 1968). To protein determination,
60 μL of supernatant was mixed with 60 μL of copper reagent freshly
prepared. After 10 min, 180 μL of Folin solution was added. The
resulting solution was incubated at 50 °C for 10 min. The absorbance
was measured at 660 nm and the results equated to a standard curve
of bovine serum albumin (Lowry et al., 1951).
2.10. FRAP and ABTS assays
Paw skin sample was collected and immediately homogenized with
500 μL of 1.15% KCl, and was centrifuged (10 min × 200 g × 4 °C). The
ability of sample to resist oxidative damagewas determined as ferric re-
ducing ability by FRAP assay, and as free radical scavenging ability by
ABTS assay (Katalinic et al., 2005; Re et al., 1999). For FRAP assay,
50 μL of supernatant was mixed with 150 μL of deionized water and
1.5 mL of FRAP reagent freshly prepared. The reaction mixture was in-
cubated at 37 °C for 30 min and the absorbance was measured at
595 nm. For ABTS assay, ABTS solution was diluted with phosphate
buffer saline pH 7.4 (PBS) to an absorbance of 0.80 at 730 nm. Then,
1.0 mL of diluted ABTS solution was mixed to 20 μL of supernatant.
After 6 min, the absorbance was measured at 730 nm. The results
were equated against a Trolox standard curve (1.5–30 μmol/L,ﬁnal con-
centrations). The results are expressed as Trolox equivalents per gram
of tissue weight in both assays.
2.11. Experimental procedures
For this study, mice received per oral (p.o.) pretreatmentwith pirac-
etam (10–300 mg/kg/10 mL diluted in saline) 60 min before inﬂam-
matory stimulus or post-treatment 30 min after carrageenin or
starting 24 h after CFA injection. Local treatment with piracetam (10,
30, 100 and 300 μg/paw/25 μL diluted in saline) was also performed.
The doses of inﬂammatory stimuli were determined in our laboratory
and based on previous studies (Cunha et al., 2005; Mizokami et al.,
2012; Pavão-de-Souza et al., 2012; Valério et al., 2007, 2009; Verri et
al., 2008; Zarpelon et al., 2012, 2013). The writhing response was eval-
uated for 20 min after i.p. injection of PBQ (1890 μg/kg) or acetic acid
0.6% (10 mL/kg). The nociceptive behavior of licking the pawwas quan-
tiﬁed for 30 min after formalin 2.5% (25 μL/paw) or CFA (10 μL/paw)
injection. Mechanical hyperalgesia was evaluated 1–5 h after carra-
geenin (100 μg/25 μL/paw) or TNF-α (100 pg/25 μL/paw) injection,and 1–7 days after injection of CFA (10 μL/paw). All inﬂammatory stim-
uli induced only ipsilateral (in the paw in which the stimulus was
injected)mechanical hyperalgesia. Thermal hyperalgesiawas evaluated
1–5 h after carrageenin (100 μg/25 μL/paw) and 1–7 days after injec-
tion of CFA (10 μL/paw). Neutrophil migration was evaluated in paw
skin by myeloperoxidase activity assay 5 h after carrageenin (100 μg/
25 μL/paw) or TNF-α (100 pg/25 μL/paw) injection. IL-1β and TNF-α
levels were measured in paw skin 3 h after carrageenin injection, and
IL-1β level was also determined 3 h after TNF-α injection. The GSH
level and FRAP and ABTS assay were evaluated 3 h after carrageenin
injection.
2.12. Statistical analysis
Results are presented as means ± SEM of measurements made on
6 mice in each group per experiment. Experiments were performed
twice. Two-way analysis of variance (ANOVA) was used to compare
the groups and doses at all times (curves). The analyzed factors
were treatments, time and time versus treatment interaction. When
there was a signiﬁcant time versus treatment interaction, one-way
ANOVA followed by Bonferroni's t-test was performed for each
time. On the other hand, when the nociceptive responses were
presented as total values at indicated time period, the differences be-
tween responses were evaluated by one-way ANOVA followed by
Bonferroni's t-test. Statistical differences were considered to be sig-
niﬁcant at P b 0.05.
3. Results
3.1. Piracetam reduces pain-like behavior induced by varied stimuli
In the ﬁrst series of experiments, the analgesic effect of piracetam
was evaluated in acetic acid-, PBQ-, formalin- and CFA-induced
pain-like behaviors. Mice were treated with piracetam (10–300 mg/
kg, p.o.) 1 h before the i.p. stimulus with acetic acid (Fig. 1A). The
dose of 10 mg/kg of piracetam did not affect while the doses of 30,
100 and 300 mg/kg of piracetam reduced in a signiﬁcant manner
the abdominal contortion induced by acetic acid (Fig. 1A). The effect
of 100 and 300 mg/kg of piracetam was signiﬁcant when compared
to the dose of 10 mg/kg of piracetam. Therefore, the dose of
100 mg/kg was selected for the following experiments on overt
pain-like behavior. Piracetam inhibited PBQ-induced abdominal con-
tortions with up to 41% inhibition (Fig. 1B). In the formalin test, pirac-
etam reduced the ﬁrst (5 min) and second phases (20 and 25 min) of
licking response (Fig. 1C). In the CFA test, the treatment with pirace-
tam also reduced the licking response (Fig. 1D).
3.2. Piracetam reduces carrageenin-induced mechanical and thermal
hyperalgesia and myeloperoxidase activity
Mice were treated with piracetam (10–100 mg/kg, p.o.) 1 h be-
fore i.pl. stimulus with carrageenin (100 μg) (Fig. 2). Piracetam re-
duced in a dose-dependent manner the mechanical hyperalgesia
induced by carrageenin (Fig. 2A). There was a tendency of reduction
of mechanical hyperalgesia by 10 mg/kg of piracetam that was not
signiﬁcant (Fig. 2A). The dose of 30 mg/kg of piracetam reduced
carrageenin-induced mechanical hyperalgesia at 3 h. The dose of
100 mg/kg of piracetam reduced the mechanical hyperalgesia in-
duced by carrageenin at 3 and 5 h. At 3 h the effect of piracetam
100 mg/kg was signiﬁcant compared to the lower doses of piracetam
and at 5 h compared to the dose of 10 mg/kg (Fig. 2A). In the hot
plate test, the dose of 100 mg/kg of piracetam reduced the thermal
hyperalgesia induced by carrageenin at 3 and 5 h without alterations
by the doses of 10 and 30 mg/kg of piracetam (Fig. 2B). At 5 h, mice
were sacriﬁced and samples of paw plantar skin were collected for
MPO activity assay (Fig. 2C). Only the dose of 100 mg/kg of piracetam
Fig. 1. Piracetam reduced overt pain-like behavior induced by acetic acid, PBQ, formalin and CFA. Mice were treated with piracetam p.o. (10, 30, 100 or 300 mg/kg) 60 min before
i.p. injection of acetic acid 0.6% (panel A) or PBQ 1890 μg/kg (panel B), or i.pl. injection of 25 μL of formalin 2.5% (panel C) or 10 μL of CFA (panel D). The total number of writhing
was evaluated for 20 min (A and B) and the time spent licking the paw for 30 min (C and D). n = 6. * P b 0.05 compared with the saline group, # P b 0.05 compared with the stim-
ulus group, ** P b 0.05 compared with the stimulus group and the dose of 10 mg/kg of piracetam.
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100 mg/kg of piracetam was the dose selected for the next
experiment.
3.3. Post-treatment with piracetam reduces carrageenin- and CFA-
induced mechanical and thermal hyperalgesia
Mice were treated with piracetam (100 mg/kg, p.o.) 30 min after
the i.pl. injection of carrageenin (100 μg/paw), and mechanical
(Fig. 3A) and thermal (Fig. 3B) hyperalgesia were evaluated 1, 3 and
5 h after treatment. Piracetam reduced mechanical hyperalgesia at 1,
3 and 5 h, and thermal hyperalgesia at 3 and 5 h after treatment with
piracetam. In another experimental setting, mice received i.pl. injection
of CFA (10 μL/paw), andmicewere treated daily during 7 dayswith pir-
acetam (30, 100 and 300 mg/kg, p.o.) starting 24 h after CFA stimulus.
Five hours after each treatment, mechanical and thermal hyperalgesia
were evaluated (Fig. 3C and D). Piracetam reduced in a dose-
dependent manner the mechanical hyperalgesia induced by CFA, with
signiﬁcant effects at 30, 100 and 300 mg/kg. There were statistical dif-
ferences comparing the dose of 100 and 300 mg/kg to the CFA control
group and piracetam at 30 mg/kg (Fig. 3C). The dose of piracetam of
30 mg/kg did not reduce CFA-induced thermal hyperalgesia while thedoses of 100 and 300 mg/kg were effective in all 7 days. Piracetam at
100 mg/kg dose was also effective compared to 30 mg/kg at days 1
and 2, and the dose of 300 mg/kg was effective compared to the dose
of 30 mg/kg between 1 and 5 days (Fig. 3D).
3.4. Local treatment with piracetam reduces carrageenin-induced me-
chanical and thermal hyperalgesia
Mice were treated with piracetam (10, 30, 100 and 300 μg/paw)
30 min before i.pl. injection of carrageenin (100 μg/paw), and at indicat-
ed time points, mechanical (Fig. 4A) and thermal (Fig. 4B) hyperalgesia
were evaluated. Piracetam reduced in a dose-dependentmanner theme-
chanical hyperalgesia induced by carrageenin (Fig. 4A). Therewas signif-
icant reduction of mechanical hyperalgesia by piracetam at the doses of
30, 100 and 300 μg/paw at 3 and 5 h. Additionally, the dose of 100 μg/
paw presented statistical differences with the dose of 10 μg/paw at 3 h
and with the doses of 10 and 30 μg/paw at 5 h. Piracetam at 300 μg/
paw dose also presented statistical differences compared to the doses
of 10 and 30 μg/paw at 3 and 5 h. Piracetam also inhibited thermal
hyperalgesia at doses of 30, 100 and 300 μg/paw compared to control
carrageenin and lower dose of piracetam at 3 and 5 h (Fig. 4B). In addi-
tion, piracetam at 300 μg/paw also reduced carrageenin-induced
Fig. 2. Piracetam reduced carrageenin-induced mechanical hyperalgesia, thermal
hyperalgesia and myeloperoxidase activity. Mice were treated with piracetam p.o.
(10, 30 or 100 mg/kg) 60 min before carrageenin (100 μg/paw) injection. The me-
chanical and thermal hyperalgesia were evaluated 1, 3 and 5 h after carrageenin injec-
tion (panels A and B respectively). The neutrophil migration (myeloperoxidase
activity) was measured 5 h after the carrageenin injection (panel C). n = 6.
* P b 0.05 compared with the saline group, # P b 0.05 compared with the carrageenin
group, ** P b 0.05 compared with the carrageenin group and the dose of 10 mg/kg of
piracetam, ## P b 0.05 compared with the carrageenin group, the dose of 10 and
30 mg/kg of piracetam.
187S.A. Navarro et al. / Pharmacology, Biochemistry and Behavior 105 (2013) 183–192thermal hyperalgesia at 1 h. Considering that there were no statistical
differences between the doses of piracetam of 100 and 300 μg/paw,
the dose of 100 μg/paw was selected for next experiments (Fig. 4C
and D). The contra-lateral (CL) treatment with piracetam did not
affect the mechanical (Fig. 4C) and thermal (Fig. 4D) hyperalgesia
induced by carrageenin. Furthermore, the local treatment with
piracetam did not alter the mechanical (Fig. 4C) or thermal (Fig. 4D)
threshold per se.
3.5. Piracetam reduces carrageenin-induced IL-1βwithout affecting TNF-
α production in paw skin
Micewere treatedwith piracetam as described in Fig. 2 and received
i.pl. injection of carrageenin (100 μg) and samples were collected after
3 h. Piracetam signiﬁcantly inhibited the carrageenin-induced produc-
tion of IL-1β (Fig. 5A) in the paw (41%)without affecting TNF-αproduc-
tion (Fig. 5B).
3.6. Piracetam reduces TNF-α-induced mechanical hyperalgesia, MPO
activity and IL-1β production
It has been demonstrated that in the carrageenin-induced paw in-
ﬂammation, TNF-α is responsible for inducing IL-1β production
(Cunha et al., 2005). Therefore, considering that piracetam inhibited
carrageenin-induced IL-1β productionwithout affecting TNF-α produc-
tion, it was evaluated whether piracetamwould inhibit TNF-α-induced
mechanical hyperalgesia, MPO activity and IL-1β production (Fig. 6).
Mice were treated with piracetam as described above and after 1 h re-
ceived i.pl. injection of TNF-α (100 pg/paw). Piracetam reduced
TNF-α-induced mechanical hyperalgesia at 1, 3 and 5 h (Fig. 6A),
MPO activity at 5 h (Fig. 6B) and IL-1β production at 3 h (Fig. 6C).
3.7. Piracetam reduces carrageenin-induced decrease in antioxidant defenses
Mice were treated with piracetam as described above before car-
rageenin i.pl. injection and paw skin samples were collected after ad-
ditional 3 h for GSH, FRAP and ABTS assays (Fig. 7). Carrageenin
reduced the endogenous GSH skin levels (Fig. 7A), ferric reducing
ability (FRAP assay; Fig. 7B) and free radical scavenging ability
(ABTS assay; Fig. 7C), and piracetam treatment prevented these re-
ductions of antioxidant defenses in the skin.
4. Discussion
Piracetam is a nootropic drug that has been used to treat cognitive
impairment. The present study provides evidence that piracetam ex-
erts analgesic effects upon varied inﬂammatory stimuli by mecha-
nisms related to reduction of MPO activity, IL-1β production, and
oxidative stress.
There is one previous evidence that piracetam could present anal-
gesic effects in the acetic acid writhing test (Abdel-Salam, 2006).
Herein, we conﬁrmed and extended this evidence to additional
models of overt pain-like behavior including acetic acid- and PBQ-
induced writhing response and formalin- and CFA-induced paw lick-
ing. Furthermore, it was observed that piracetam also reduced me-
chanical and thermal hyperalgesia induced by carrageenin and CFA,
and mechanical hyperalgesia induced by TNF-α. Importantly, pirace-
tam exerted analgesic effect as post-treatment in the mechanical and
thermal hyperalgesia induced by carrageenin and CFA. The impor-
tance of these data is that the analgesic effect of piracetam was ob-
served in varied models and post-treatment, which increases the
probability of its possible clinical applicability. In agreement, pirace-
tam has been used as a nootropic drug for about 40 years with low
adverse reaction in clinical settings, thus, reducing the steps needed
to use piracetam as an analgesic. Moreover, according to the package
insert of Nootropil®, the treatment with piracetam ranges from 2.4 to
Fig. 3. Post-treatment with piracetam diminished carrageenin-induced mechanical and thermal hyperalgesia. Mice were treated with piracetam (30–300 mg/kg, p.o.) 30 min after
carrageenin (100 μg/paw) (panels A and B) and daily starting at 24 after CFA (10 μg/paw; panels C and D). Mechanical and thermal hyperalgesia were evaluated 1–5 h after treat-
ment (panels A and B, respectively) or 5 h after each daily treatment with piracetam (panels C and D, respectively). n = 6. * P b 0.05 compared with the saline group, # P b 0.05
compared with the stimulus group, ** P b 0.05 compared with the CFA group and the dose of 30 mg/kg of piracetam.
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dose range would be 34 to 171 mg/kg. In the present study, the pirac-
etam optimal analgesic dose of 100 mg/kg was selected over a dose–
response curve. Therefore, the analgesic dose of piracetam would be
within the present dose range in clinical use.
The thermal hyperalgesia analyzed in the hot plate test in naïve
animals is considered to involve supraspinal nociceptive mechanisms
(Le Bars et al., 2001). Previous study reported that piracetam alone
does not alter the basal latency in hot plate test (Abdel-Salam,
2006), indicating that piracetam does not present supraspinal analge-
sic mechanisms in thermal hyperalgesia. In the present study, pirace-
tam reduced carrageenin- and CFA-induced thermal hyperalgesia,
suggesting that piracetam acts mainly in the peripheral inﬂammatory
component of pain, which is responsible for nociceptor sensitization
in this model. The peripheral injection of carrageenin also induces
the spinal microglia activation and peripheral inhibition of inﬂamma-
tion will result in diminished spinal activation (Hua et al., 2005).
Corroborating the importance of peripheral action of piracetam,
it was also observed that local i.pl. treatment with piracetam dimin-
ished carrageenin-induced mechanical and thermal hyperalgesia.Moreover, conﬁrming the peripheral effect of the i.pl. treatment
with piracetam, the treatment of the contra-lateral paw to the stimu-
lus did not present analgesic effect in the ipsilateral paw to the
stimulus.
The varied models of inﬂammatory pain used in the present study
share some pain mechanisms such as the production of nociceptive
cytokines including IL-1β in the acetic acid, PBQ, second phase of for-
malin test, CFA, carrageenin and administration of TNF-α models
(Chichorro et al., 2004; Cunha et al., 2005; Ribeiro et al., 2000; Verri
et al., 2006a, 2008). Therefore, a reasonable mechanism of action to
be investigated was whether piracetam would reduce pain-like be-
havior by reducing the production of nociceptive cytokines. In fact,
piracetam reduced IL-1β production induced by carrageenin adminis-
tration. However, piracetam did not affect carrageenin-induced
TNF-α production. A possible explanation for this selective inhibition
of IL-1β production could rely on the nociceptive mechanisms trig-
gered by carrageenin in which IL-1β production depends on TNF-α
(Cunha et al., 2005). In fact, piracetam reduced TNF-α-induced me-
chanical hyperalgesia and IL-1β production. To our knowledge, this
is the ﬁrst demonstration that piracetam decreases IL-1β production.
Fig. 4. Local treatment with piracetam diminished carrageenin-induced mechanical and thermal hyperalgesia. Mice were pretreated with piracetam i.pl. (10–300 μg/paw) 30 min
before carrageenin injection (100 μg/paw). Mice received the treatment and stimulus in the ipsilateral paw (panels A and B) or treatment in the contra-lateral (CL) paw to the stim-
ulus (panels C and D). Mechanical and thermal hyperalgesia were evaluated 1–5 h after stimulus. n = 6. * P b 0.05 compared with the saline group, # P b 0.05 compared with the
carrageenin group, ** P b 0.05 compared with the carrageenin group and the dose of 10 μg/kg of piracetam, ## P b 0.05 compared with the carrageenin group and the dose of 10 μg/
kg and 30 μg/kg of piracetam, ƒ P b 0.05 compared with the piracetam only group and the saline only group.
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the immunoreactivity to IL-1β and IL-1R1 by activated astrocytes
and microglia of epileptic rats (Kim et al., 2010). Levetiracetam re-
duced the mRNA expression for TNF-α in a rat model of temporal
lobe epilepsy (Christensen et al., 2010), which would contribute to
explain an analgesic effect of piracetam, and is not in contradiction
to the present study since we analyzed TNF-α protein levels and
not mRNA expression.
Another important component of carrageenin-induced hyperalgesia
is the recruitment of neutrophils, which may contribute to mechanical
hyperalgesia by further producing nociceptive molecules including
PGE2 (Cunha et al., 2008). Piracetam also reduced the MPO activity in
the paw skin induced by carrageenin and TNF-α, suggesting that reduc-
tion of neutrophil recruitment could be part of the analgesic effect of
piracetam. Corroborating the result on MPO activity in paw skin sam-
ples, piracetam reduced carrageenin-induced neutrophil recruitment
to the peritoneal cavity (unpublished observation of Navarro SA et
al.). These data are also in line with the inhibition of carrageenin- and
TNF-α-induced IL-1β production, since IL-1β is a chemoattractant cyto-
kine for neutrophils (Verri et al., 2010). The inhibition of IL-1βproduction diminishes chemoattraction of neutrophils due to reduced
expression of adhesion molecules and production of IL-1β-dependent
mediators (Verri et al., 2010). Furthermore, reactive oxygen species
are also contributing molecules to the recruitment of neutrophils and
the inhibition of oxidative stress observed herein is also an explanation
for reduced neutrophil chemotaxis (Hattori et al., 2010).
In fact, cytokines are also closely related to oxidative stress. TNF-α
and IL-1β activate NADPH oxidase inducing the production of super-
oxide anion starting the generation of reactive oxygen species
(Lambeth, 2004; Drummond et al., 2011). In turn, superoxide anion
can induce cytokine production by activation of NFκB (Verri et al.,
2012). Oxidative stress is a contributing factor to inﬂammatory
hyperalgesia together with inﬂammatory cytokines (Verri et al.,
2012). Further corroborating an intricate analgesic mechanism of action
of piracetam, in the present study it prevented the carrageenin-induced
decrease of endogenous GSH, ferric reducing ability (FRAP assay) and
free radical scavenging ability (ABTS assay). Furthermore, the present
data on reduction of oxidative stress by piracetam are in accordance
with the demonstration that it inhibited ethidium bromide-induced
acute demyelination of the rat brain that depends on GSH depletion
Fig. 5. Piracetam reduced carrageenin-induced IL-1β production without affecting
TNF-α production. Mice were treated with piracetam p.o. (100 mg/kg) 60 min before
i.pl. injection of carrageenin (100 μg/paw) and 3 h after stimulus IL-1β (panel A) and
TNF-α (panel B) levels were determined by ELISA. n = 6. * P b 0.05 compared with
the saline group, # P b 0.05 compared with the carrageenin group.
Fig. 6. Piracetam reduced TNF-α-induced mechanical hyperalgesia, myeloperoxidase
activity and IL-1β production. Mice were treated with piracetam p.o. (100 mg/kg)
60 min before TNF-α (100 pg/25 μL/paw) injection. Mechanical hyperalgesia was
evaluated 1–5 h after TNF-α injection (panel A), neutrophil migration was evaluated
by MPO assay 5 h after TNF-α injection (panel B), and IL-1β level was determined by
ELISA 3 h after TNF-α injection (panel C). n = 6. * P b 0.05 compared with the saline
group, # P b 0.05 compared with the TNF-α control group.
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phosphamidon-induced increase in brain malondialdehyde levels (e.g.
lipid peroxidation) (Gupta et al., 2009; Kosta et al., 2013). Additionally,
the reduction of leukocyte recruitment could account for impairing
oxidative stress since leukocytes such as neutrophils that are recruited
in the initial hours of inﬂammation produce reactive oxygen species
(Lambeth, 2004; Drummond et al., 2011).
In addition to the effects of piracetam on cytokine production, ox-
idative stress and MPO, it was noticeable that it reduced the ﬁrst
phase of formalin-induced licking response, which suggests a possi-
ble neuronal effect of piracetam. Previous evidence demonstrates
that the ﬁrst phase of the formalin test depends, at least in part, on
serotonin release and action on nociceptors (Parada et al., 2001).
Considering that the analgesic effects of levetiracetam were
inhibited by serotonin receptor antagonist (Micov et al., 2010), and
piracetam reduces the release of serotonin (Nalini et al., 1992), it is
possible that inhibition of serotonin release explains, at least in
part, the inhibition of the ﬁrst phase of the formalin test by treatment
with piracetam.
Concluding, piracetam reduces inﬂammatory pain by mechanisms
related to reduction of peripheral cytokine production, MPO activity
and oxidative stress, demonstrating previously unrecognized analge-
sic mechanisms of piracetam. Therefore, the present study suggests
the potential use of piracetam as an analgesic, which merits further
clinical investigation.
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Fig. 7. Piracetam reduced carrageenin-induced decrease of GSH level and
anti-oxidative capacity in FRAP and ABTS assays. Mice were treated with piracetam
p.o. (100 mg/kg) 60 min before carrageenin (100 μg/paw) injection. Samples for GSH
level measurement (panel A), FRAP (panel B, ferric reducing ability) and ABTS (panel
C, free radical scavenging ability) assays were collected 3 h after stimulus injection.
n = 6. * P b 0.05 compared with the saline group, # P b 0.05 compared with the carra-
geenin group.
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